[1]李海燕.血清人附睾蛋白4和糖类抗原125在卵巢上皮性癌治疗前后的变化及对近期预后的影响[J].中国计划生育和妇产科,2017,(12):61-63.
　LI Hai-yan.Changes of serum HE4 and CA125 before and after treatment of epithelial ovarian cancer and their effects on short-term prognosis[J].Chinese Journal of Family Planning & Gynecotokology,2017,(12):61-63.
点击复制

血清人附睾蛋白4和糖类抗原125在卵巢上皮性癌治疗前后的变化及对近期预后的影响
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2017年12期
页码:
61-63
栏目:
论著与临床
出版日期:
2017-12-25

文章信息/Info

Title:
Changes of serum HE4 and CA125 before and after treatment of epithelial ovarian cancer and their effects on short-term prognosis
作者:
李海燕
遂宁市中医院妇科
Author(s):
LI Hai-yan
Department of Gynecology,Suining Municipal Hospital of TCM,Suining Sichuan 629125,P.R.China
关键词:
卵巢上皮性癌; 人附睾蛋白4; 糖类抗原125; 近期预后
Keywords:
epithelial ovarian cancer;  HE4;  CA125;  short-term prognosis
分类号:
R 73731
摘要:
目的探究血清人附睾蛋白4(human epididymis protein 4,HE 4)和糖类抗原125(carbohydrate antigen 125, CA 125)在卵巢上皮性癌治疗前后的水平变化及对患者近期预后的影响。方法选取2011年3月至2014年1月于遂宁市中医院治疗的465例卵巢上皮性癌患者为观察组，另选取465例健康体检对象为对照组。比较两组对象血清HE 4及CA 125水平的差异及观察组患者治疗前后两指标水平的变化，并分析血清CA 125水平对患者近期预后的影响。结果观察组患者治疗前血清HE 4和CA 125水平显著高于对照组，差异有统计学意义（P<005）；治疗后观察组患者的血清HE 4和CA 125水平均降至正常水平，与治疗前相比差异有统计学意义（P<005）；36个月内发生不良事件患者治疗前血清CA 125水平更高。结论治疗前卵巢上皮性癌患者血清HE 4和CA 125水平显著高于正常健康人群，治疗后血清HE 4和CA 125水平显著降低，基础血清CA 125水平更高者近期预后较差。
Abstract:
ObjectiveTo study the changes of serum HE4 and CA125 in epithelial ovarian cancer patients before and after treatment and their effects on short-term prognosis. Methods465 patients with epithelial ovarian cancer treated in Suining Municipal Hospital of TCM from March 2011 to January 2014 were selected as the observation group, another 465 healthy patients were selected as the control group. The levels of serum human epididymis protein 4(HE4) and carbohydrate antigen 125(CA125) of the two groups were compared, changes of the two indexes before and after treatment were observed, and the effects of serum CA125 on the short-term prognosis of patients were analyzed. ResultsThe levels of serum HE4 and CA125 in the observation group before treatment were significantly higher than those in the control group, the differences were statistically significant(P<0.05); After treatment, the levels of serum HE4 and CA125 in the observation group were decreased to normal level, and the differences were statistically significant(P<0.05); The occurrence of adverse events within 36 months were in patients with higher serum CA125 levels before treatment. ConclusionThe levels of serum HE4 and CA125 in patients with epithelial ovarian cancer before treatment were significantly higher than those in the normal population. After treatment, the levels of serum HE4 and CA125 were significantly lower.The patients with higher serum CA125 levels before treatment has poor short-term prognosis.

参考文献/References:

［1］BAR J K, GRELEWSKI P, IS N A, et al. The role of cancer stem cells in progressive growth and resistance of ovarian cancer:true or fiction ［J］. Postepy Higieny i Medycyny Doswiadczalnej (Online), 2015, 69(10): 1077-1086. ［2］YAHARA K, OHGURI T, IMADA H, et al. Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy ［J］. Journal of Radiation Research, 2013, 54(2): 322-329. ［3］黄立．血清CA 125水平变化与上皮性卵巢癌复发相关因素之间关系的探讨 ［D］．沈阳：中国医科大学，2004． ［4］陈华干，杨婷，朱书宇，等．血清HE 4联合CA 125检测在卵巢癌术后复发中的诊断价值 ［J］．中国妇幼保健，2016，31（18）：3696-3698． ［5］赵阳．血清HE 4、CA 125和YKL-40联合检测在上皮性卵巢癌诊断中的临床价值 ［D］．太原：山西医科大学，2014． ［6］周萍，袁建林，马秀萍，等．上皮性卵巢癌患者手术及化疗前后血清中人附睾蛋白4 和糖类抗原125的变化 ［J］．中国肿瘤临床与康复，2014，21（5）：531-533． ［7］马二玲，刘越飞，刘晓旭，等．HE 4作为卵巢癌肿瘤标志物的研究进展 ［J］．河北医药，2012，34（1）：112-115． ［8］BINGLE L, SINGLETON V, BINGLE C D. The putative ovarian tumor marker gene HE4(WFDC 2),is experessed in normal tissues and undeigoes complex alternative splicing to yield multiple protein isoforms ［J］. Oncogene, 2002, 21(17): 2768-2773. ［9］霍怡杉，黄艳春，王飞．人附睾蛋白4与CA 125联合检测在卵巢癌中的诊断价值 ［J］．检验医学与临床，2014，11（1）：68-70． ［10］Markowska J, Wilkoszarska J, Emeireh J, et al. Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence ［J］. Eur J Gynaecol Oncol, 2000, 21(2), 164-167. ［11］GEISLER J P, MILLER G A, LEE T H, et al. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma ［J］. The Journal of Reproductive Medicine, 1996, 41(3): 140-142.

相似文献/References:

[1]徐萌,李慧源.联合检测血清HE4和CA125对卵巢恶性肿瘤的诊断价值[J].中国计划生育和妇产科,2011,(03):0.
　XU Meng,LI Hui-yuan ..[J].Chinese Journal of Family Planning & Gynecotokology,2011,(12):0.
[2]邱伟,刘敏,吴土连,等.间歇性肿瘤细胞减灭术中残余病灶变化对晚期卵巢上皮性癌术后化疗的预后评价[J].中国计划生育和妇产科,2015,(10):0.
　QIU Wei,LIU Min,WU Tu-lian,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2015,(12):0.
[3]赵长燕*,贺红梅,张明慧.血清DKK-4、nidogen-2与HE 4在卵巢浆液性 肿瘤患者中的表达及其临床意义[J].中国计划生育和妇产科,2019,(2):89.
　ZHAO Chang-yan*,HE Hong-mei,ZHANG Ming-hui.Clinical value of DKK-4 and nidogen-2 combined with HE 4 in the diagnosis of serous ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2019,(12):89.

更新日期/Last Update: 2017-12-25